Common Stock, par value $0.001 per share
- Symbol
- CHRN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
ChronoScale Holdings Corporation
CHRNNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On October 15, 2026, ChronoScale Holdings Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended August 31, 2026. A copy of such press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.…
Press release in this filing
ChronoScale Reports Fiscal First Quarter 2027 Results →Company context
Current securities
Historical securities (1)
Registered securities in this filing
CHRONOSCALE HOLDINGS CORPORATION · 8-K · Filed 2026-10-15
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition
On
October 15, 2026, ChronoScale Holdings Corporation (the “Company”) issued a press release announcing its financial
results for the first fiscal quarter ended August 31, 2026.
A
copy of such press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
The
information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange
Act, regardless of any general incorporation language in such filing.
Filed exhibits (1)
Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. - October 15, 2026 - ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, reported financial results for the fiscal first quarter ended August 31, 2026. Following the business combination completed on May 5, 2026, the Company classified its legacy Ekso Bionics business (“Legacy Ekso Business”) as held for sale and reported its results in discontinued operations in accordance with U.S. generally accepted accounting principles (“GAAP”). Accordingly, Legacy Ekso Business’ results are excluded from the Company’s continuing operations and presented separately in its consolidated financial statements. Subsequent to quarter end, the Company completed the sale of the Legacy Ekso Business on September 30, 2026. Unless otherwise specified, disclosures in this earnings release, including the below, reflect continuing operations only. Fiscal First Quarter 2027 Financial Highlights Revenue: $41.5 million, up 148% from $16.7 million in the prior-year comparable period. Net …
Open exhibit ↗